Hubert Truebel
Overview
Explore the profile of Hubert Truebel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
265
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boden K, Pongratanakul P, Vogel J, Willemsen N, Julke E, Balitzki J, et al.
J Pharmacol Toxicol Methods
. 2023 Nov;
124:107480.
PMID: 37979811
Despite medical advances in the treatment of heart failure (HF), mortality remains high. It has been shown that alterations of the autonomic-nervous-system (ANS) are associated with HF progression and increased...
2.
Bieske L, Zinner M, Dahlhausen F, Truebel H
Drug Discov Today
. 2023 Aug;
28(10):103733.
PMID: 37544639
Most clinical trials are delayed due to scientific and/or operational challenges. Any effort to minimize delays can generate value for patients and sponsors. This article reviews critical path process steps...
3.
Bade C, Olsacher A, Boehme P, Truebel H, Fehring L
Res Social Adm Pharm
. 2023 May;
19(8):1218-1227.
PMID: 37225602
Background: Drug shortages impact multiple stakeholders and are detrimental to patient safety. Additionally, drug shortages are an extensive financial burden. In Germany, drug shortages, according to data from the federal...
4.
Scannell J, Bosley J, Hickman J, Dawson G, Truebel H, Ferreira G, et al.
Nat Rev Drug Discov
. 2022 Oct;
21(12):915-931.
PMID: 36195754
Successful drug discovery is like finding oases of safety and efficacy in chemical and biological deserts. Screens in disease models, and other decision tools used in drug research and development...
5.
Truebel H, Seidler M
Nat Rev Drug Discov
. 2022 Sep;
21(12):874-875.
PMID: 36167985
No abstract available.
6.
Schmidt A, Balitzki J, Grmaca L, Vogel J, Boehme P, Boden K, et al.
Heart Fail Rev
. 2022 Aug;
28(1):249-260.
PMID: 36001250
Innovations in the development of novel heart failure therapies are essential to further increase the predictive value of early research findings. Animal models are still playing a pivotal role in...
7.
Kuck A, Kinscher K, Fehring L, Hildebrandt H, Doerner J, Lange J, et al.
Int J Environ Res Public Health
. 2022 Jul;
19(14).
PMID: 35886327
Background: Value-Based Care (VBC) is being discussed to provide better outcomes to patients, with an aim to reimburse healthcare providers (HCPs) based on the quality of care they deliver. Little...
8.
Schramm L, Monsefi N, Huser J, Truebel H, Mondritzki T
Drug Discov Today
. 2021 Dec;
27(5):1326-1331.
PMID: 34958958
Although 'unmet medical need' (UMN) is an increasingly used term in the healthcare sector instrumental to the approximate value of drug discovery projects relevant to portfolio management, no standardized approach...
9.
Neumann M, Fehring L, Kinscher K, Truebel H, Dahlhausen F, Ehlers J, et al.
GMS J Med Educ
. 2021 Dec;
38(7):Doc124.
PMID: 34957329
The German healthcare sector is in the process of being disrupted by digitization. Universities are asked to reflect on the consequences and develop strategies to prepare their medical students for...
10.
Vogel J, Boehme P, Homann S, Boehm M, Schutt K, Boden K, et al.
Hypertens Res
. 2021 Sep;
44(12):1568-1577.
PMID: 34548653
Therapy-resistant hypertension is a serious medical problem, causing end-organ damage, stroke, and heart failure if untreated. Since the standard of care fails in resistant hypertension patients, there is still a...